• Tango Therapeutics President, R&D Crystal Adam exercised stock options for 27,000 shares at USD 5.2 on July 1, 2026.
• Adam sold 27,000 shares the same day for weighted average prices of USD 29.34 and USD 30.25.
• Her direct common stock holdings fell to 115,743 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-295124), on July 02, 2026, and is solely responsible for the information contained therein.